Equities

Profile data is unavailable for this security.

About the company

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

  • Revenue in USD (TTM)80.50bn
  • Net income in USD14.89bn
  • Incorporated1887
  • Employees132.20k
  • Location
    Johnson & Johnson1 Johnson And Johnson PlzNEW BRUNSWICK 08933-0001United StatesUSA
  • Phone+1 (732) 524-2455
  • Fax+1 (732) 214-0332
  • Websitehttps://www.jnj.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
JNJ:NYQ since
announced
Transaction
value
Momenta Pharmaceuticals IncAnnounced19 Aug 202019 Aug 2020Announced-2.95%6.55bn
Taris Biomedical LLCDeal completed20 Dec 201920 Dec 2019Deal completed0.21%--
Verb Surgical IncDeal completed20 Dec 201920 Dec 2019Deal completed0.21%--
Data delayed at least 15 minutes, as of Sep 26 2020 00:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences, Inc.22.17bn-257.00m78.04bn11.80k--4.3370.373.52-0.2426-0.242617.5114.380.37224.916.731,879,153.00-0.481818.07-0.577621.8878.5783.42-1.2939.312.23-18.130.570525.341.46-2.04-1.34-14.958.17--
Bristol-Myers Squibb Co34.86bn-563.00m134.09bn30.00k--2.7322.303.85-0.1033-0.103317.2721.780.38055.686.221,162,067.00-0.58948.56-0.720311.2169.9472.59-1.5517.511.368.690.48772.4515.8910.49-30.8911.419.712.64
Amgen, Inc.24.30bn7.30bn142.80bn23.40k19.9213.4113.825.8812.2412.2440.7618.180.39071.515.301,038,504.0011.7410.8314.1412.6778.2381.7530.0434.011.8110.320.762541.54-1.623.09-6.588.74-9.2318.91
Eli Lilly And Co22.95bn5.62bn143.72bn33.63k24.4535.1121.006.266.156.1525.104.280.56921.514.41682,521.9013.938.7619.8812.2878.6776.6224.4816.770.939922.640.792664.423.842.6239.4514.17-2.875.65
AbbVie Inc36.23bn6.91bn152.18bn47.00k18.9710.3415.024.204.554.5523.288.340.35063.255.241,207,567.006.739.908.4312.7273.3177.1419.2021.340.69786.350.855879.291.5710.7636.5534.62-2.0420.86
Pfizer Inc.49.20bn13.85bn200.33bn88.30k14.673.1110.394.072.462.528.7511.580.29451.155.20557,157.408.316.2710.327.6880.4379.4028.2020.231.16--0.496373.76-3.540.850354.1511.9110.386.72
Merck & Co., Inc.47.19bn10.53bn209.75bn71.00k20.097.5914.774.444.134.1118.4810.930.54072.216.07664,704.3012.096.5015.978.2772.0767.9322.3514.301.05135.670.526788.9810.752.0953.02-3.5321.405.13
Johnson & Johnson80.50bn14.89bn383.50bn132.20k26.136.0917.514.765.575.6930.1523.920.51362.955.50608,948.609.5010.5112.1313.1565.7667.8318.4920.070.9917--0.325558.890.58592.00-1.16-1.52-1.196.32
Data as of Sep 26 2020. Currency figures normalised to Johnson & Johnson's reporting currency: US Dollar USD

Institutional shareholders

27.34%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2020219.27m8.33%
SSgA Funds Management, Inc.as of 30 Jun 2020152.57m5.80%
BlackRock Fund Advisorsas of 30 Jun 2020129.83m4.93%
Geode Capital Management LLCas of 30 Jun 202039.57m1.50%
State Farm Investment Management Corp.as of 30 Jun 202034.57m1.31%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202033.97m1.29%
Massachusetts Financial Services Co.as of 30 Jun 202029.59m1.12%
Wellington Management Co. LLPas of 30 Jun 202028.77m1.09%
Norges Bank Investment Managementas of 31 Dec 201928.38m1.08%
BlackRock Investment Management (UK) Ltd.as of 30 Jun 202023.26m0.88%
More ▼
Data from 31 Dec 2019 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.